Mark Coyne

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 385 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

The Interleukin 1 Gene Cluster Contains a Major Susceptibility Locus for Ankylosing Spondylitis

Andrew E. Timms, Alison M. Crane, Anne-Marie Sims et al. · The American Journal of Human Genetics · 2004 · 128 citations · Full text

Life Sciences, Genetics, Immunology +15

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Meletios Α. Dimopoulos, Paul G. Richardson, Nizar J. Bahlis et al. · The Lancet Haematology · 2022 · 47 citations

Medicine, Oncology, Pharmacotherapy +12

Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK

Julian D. Gillmore, Mary M. Reilly, Caroline Coats et al. · Advances in Therapy · 2022 · 31 citations · Full text

Life Sciences, Genetics, Neurology +16

Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models

Alessandro Natoni, Mark Coyne, Alan J. Jacobsen et al. · Cancers · 2013 · 22 citations · Full text

Medicine, Oncology, Pharmacology +17